Agreement to Commercialize CRISPR Tools and Reagents
Product News Jan 07, 2020
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, has signed an agreement with New England Biolabs (NEB®), granting NEB rights to sell CRISPR/Cas9 tools and reagents.
NEB offers recombinant and native enzymes for genomic research and aims to continue expanding its product offerings into new areas of research, including genome editing. As a provider of CRISPR/Cas9 reagents and tools, NEB’s license from ERS Genomics expands the Company’s rights to use and sell these technologies.
ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational IP covering CRISPR/Cas9. Companies can obtain licenses to this technology for internal research and commercialization of research tools, kits, reagents and genetically modified cell lines and organisms.